Issue link: https://beckershealthcare.uberflip.com/i/1510256
Stratified by Eosinophil Counts Switch Cohorts IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS (cont'd) Acute Asthma Symptoms or Deteriorating Disease FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm. Reduction of Corticosteroid Dosage Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Parasitic (Helminth) Infection It is unknown if FASENRA will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves. IMPACT OF RATE OF ASTHMA EXACERBATIONS 3 FASENRA® (benralizumab) Subcutaneous Injection 30 mg 12 months pre-index 12 months post-index Rate of asthma exacerbations per person-year 3.55 3.13 3.42 3.10 1.72 1.14 1.51 1.11 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 <150 cells/µL (n=114) ≥150 cells/µL (n=315) ≥300 cells/µL (n=235) <300 cells/µL (n=194) 52 % 64 % 64 % 56 % 3.25 3.81 1.25 1.78 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 Rate of asthma exacerbations per person-year Switched from omalizumab (n=205) Switched from mepolizumab (n=144) 62 % 53 % Annual exacerbation rate reduction of were observed in patients on benralizumab who were previously on another respiratory biologic in ZEPHYR 2 53 % Annual exacerbation rate reduction of were observed in patients on benralizumab in the post-index period wtih eosinophil counts of ≥150 cells/µL and ≥300 cells/μL in ZEPHYR 2 compared with the pre-index period 64 % 52 % 56 % 62 % 64 % 64 % 53 % This is an observational study; clinical implications cannot be determined from this payer database study. The exact reasons behind a patient's switch from one medication to another cannot be ascertained from the data. The efficacy and safety of benralizumab has not been evaluated in head-to-head trials vs omalizumab or mepolizumab. Please see additional Important Safety Information throughout and Brief Summary of full Prescribing Information on adjacent pages. US-79385_US-51016 Fasenra Beckers Hospital Review Advertorial.indd 2 US-79385_US-51016 Fasenra Beckers Hospital Review Advertorial.indd 2 9/13/23 9:57 AM 9/13/23 9:57 AM